Cargando…
PSUN20 The ACSPIRE Trial: 11beta-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition for Autonomous Cortisol Secretion and Adrenal Cushing's Syndrome
BACKGROUND: HSD-1, an intracellular enzyme, converts cortisone to cortisol in tissues where cortisol excess is associated with morbidity including liver, adipose, bone, brain, muscle, skin, and eye. SPI-62 is a potent and specific HSD-1 inhibitor in development for treatment of autonomous cortisol s...
Autores principales: | Czerwiec, Frank S, Drajesk, Jeffrey, Hooper, Sarah, Hunsicker, Kimberley, Jacks, Robert, MacPherson, Jamie, Marmon, Tonya, Katz, David A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624896/ http://dx.doi.org/10.1210/jendso/bvac150.254 |
Ejemplares similares
-
PMON72 The "RESCUE" Trial: 11beta-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition for ACTH-Dependent Cushing's Syndrome
por: Czerwiec, Frank S, et al.
Publicado: (2022) -
RF21 | PSAT100 HPA Axis Modulation by a Potent Inhibitor Indicates 11Beta-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Is a Significant Contributor to Cortisol Levels
por: Katz, David, et al.
Publicado: (2022) -
An Adult With Hair Loss! a Rare Case of Non-Classical 3β Hydroxysteroid Dehydrogenase (3β HSD) Deficiency
por: Patel, Sabah, et al.
Publicado: (2021) -
SAT277 Intracellular Cortisol Control: An Approach To Reduce Cushing’s Syndrome Morbidity With Minimal Adrenal Insufficiency Risk?
por: Czerwiec, Frank S, et al.
Publicado: (2023) -
PSUN42 New-Onset Rheumatoid Arthritis After Surgical Treatment of Cushing Syndrome
por: Richstein, Ryan, et al.
Publicado: (2022)